BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Anal cancer in Iceland 1987-2003. A population based study].

[Transliterated title] Carcinoma ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.

OBJECTIVE: Anal cancer is a rare disease.

The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.

MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.

This is a nationwide, population-based study of malignant tumours of the anal region.

RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.

The average age at diagnosis was 63.4 years.

Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.

Most patients had squamous cell carcinoma (n=30).

The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).

The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).

Twelve patients had recurrent cancer.

The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).

Sixteen patients remain with disease and ten have died of anal cancer.

The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.

CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.

Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.

The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.

[MeSH-major] Anus Neoplasms / epidemiology

[MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16741319.001).

[ISSN] 0023-7213

[Journal-full-title] Læknablađiđ

[ISO-abbreviation] Laeknabladid

[Language] ice

[Publication-type] English Abstract; Journal Article

[Publication-country] Iceland

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia.

Anal intraepithelial neoplasia (AIN) is the likely precursor to anal cancer.

AIN is associated with human papillomavirus (HPV) infection, and HPV-associated genomic instability may play an important role in the progression of squamous intraepithelial neoplasia to cancer.

HPV16 DNA integration or rearrangement correlated with CNAs in host cell DNA (P = 0.007).

[MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Genome, Viral. Papillomaviridae / physiology. Virus Integration

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16186736.001).

[ISSN] 1525-4135

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] eng

[Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NCI NIH HHS / CA / R01CA54053; United States / NCI NIH HHS / CA / U01 CA66529; United States / NCI NIH HHS / CA / U01 CA70019

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: This study evaluated the performance of oral brush biopsies using standard morphological analysis and haematoxylin and eosin (HE) staining for detecting oral squamous cell carcinomas and their respective precursor lesions PATIENTS AND METHODS: Brush biopsies were obtained in 169 consecutive patients who underwent routine biopsies and histological examination for clinically suspicious oral lesions.

RESULTS: Despite a sufficient number of cells, a definite cytological diagnosis could not be established in six cases.

Thus, this technique should not be used for diagnostic proof or to exclude malignant cells in a lesion suspicious for cancer.

[MeSH-major] Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology

MedlinePlus Health Information. consumer health - Biopsy.

MedlinePlus Health Information. consumer health - Oral Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]

[Cites] Mol Cancer. 2006 Mar 23;5:11 [16556320.001]

[Cites] Dtsch Zahnarztl Z. 1981 Nov;36(11):701-3 [6946905.001]

[Cites] Br J Oral Maxillofac Surg. 1996 Oct;34(5):461-6 [8909744.001]

[Cites] Dtsch Med Wochenschr. 1978 Jan 6;103(1):17-20 [620647.001]

[Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]

[Cites] N Engl J Med. 2001 May 24;344(21):1603-7 [11372013.001]

[Cites] Mund Kiefer Gesichtschir. 2007 Jan;11(1):1-9 [17177045.001]

[Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]

[Cites] Geburtshilfe Frauenheilkd. 1991 Jan;51(1):51-3 [2026300.001]

[Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):405-8 [7536508.001]

[Cites] Dtsch Zahnarztl Z. 1981 Nov;36(11):697-700 [6946904.001]

[Cites] Ann Intern Med. 1949 Oct;31(4):661-74 [15392502.001]

[Cites] Int J Oral Maxillofac Surg. 2000 Dec;29(6):453-7 [11202330.001]

[Cites] Science. 1942 Apr 24;95(2469):438-9 [17842594.001]

[Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]

[Cites] Acta Cytol. 1963 Mar-Apr;7:107-10 [13978631.001]

[Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]

[Cites] Stomatol DDR. 1986 Dec;36(12):712-6 [2438824.001]

[Cites] J Oral Maxillofac Surg. 2006 Apr;64(4):628-35 [16546642.001]

[Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]

[Cites] J Dent Res. 1951 Jun;30(3):308-13 [14841304.001]

[Cites] Mund Kiefer Gesichtschir. 2006 Mar;10(2):89-93 [16485137.001]

[Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]

[Cites] Br J Cancer. 1971 Mar;25(1):21-4 [5581297.001]

[Cites] APMIS. 2005 Mar;113(3):208-12 [15799765.001]

[Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]

[Cites] Mund Kiefer Gesichtschir. 2002 Nov;6(6):410-4 [12447653.001]

[Cites] Gen Dent. 2000 Nov-Dec;48(6):656-60 [12004660.001]

[Cites] Head Neck. 2002 Mar;24(3):223-7 [11891953.001]

[Cites] Oral Oncol. 2002 Feb;38(2):125-30 [11854058.001]

[Cites] Int Dent J. 1968 Dec;18(4):708-23 [5252708.001]

[Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]

[Cites] Geburtshilfe Frauenheilkd. 1984 Aug;44(8):485-94 [6566637.001]

[Cites] J Indiana Dent Assoc. 2001 Summer;80(2):6-8 [11693004.001]

[Cites] Cytopathology. 1994 Feb;5(1):47-53 [8173031.001]

[Cites] Dtsch Zahnarztl Z. 1966 Jan 1;21(1):145-8 [5216203.001]

[Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]

(PMID = 18214406.001).

[ISSN] 1433-0458

[Journal-full-title] HNO

[ISO-abbreviation] HNO

[Language] ger

[Publication-type] English Abstract; Evaluation Studies; Journal Article

[Publication-country] Germany

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis.

BACKGROUND AND AIMS: Majority of cases of anal squamous cell carcinoma are human papilloma virus (HPV)-induced and result from anal intraepithelial neoplasia (AIN).

This study was conducted to examine methods which may enable the routine diagnosis of HPV-induced changes in the anal rim and the consequences of such detection especially in view of a more sensitive diagnosis of AIN.

METHODS: The study included biopsy samples from 87 patients who had been diagnosed with the following disease patterns: 47 invasive anal carcinoma, 33 AIN of varying severity and seven condylomatous lesions.

RESULTS: In 38 of 47 cases of anal carcinoma, HPV DNA could be detected via PCR (80.9%), the majority of which were HPV 16 (33/38=86.8%).

DISCUSSION: In our series, the clinical diagnosis of the invasive anal carcinoma had a high sensitivity of 93.6%, with a specificity of 80%.

In this situation, especially with high-risk patients, our findings recommend anal HPV screening in combination with anal cytology and anoscopy.

CONCLUSION: Based on our results, we urgently recommend for any histological report on excision of anal lesions to include a statement whether histological markers of HPV infection were detected.

[MeSH-major] Alphapapillomavirus / genetics. Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis

[MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Int J Colorectal Dis. 2007 Oct;22(10):1289 [16703315.001]

[Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]

[Cites] Cancer. 2003 Feb 25;99(1):57-62 [12589647.001]

[Cites] Br J Cancer. 1998 Dec;78(11):1534-8 [9836490.001]

[Cites] Cytopathology. 1998 Feb;9(1):15-22 [9523124.001]

[Cites] Cancer Res. 2002 Dec 1;62(23):7075-82 [12460929.001]

[Cites] Cancer Res. 2003 Mar 15;63(6):1398-404 [12649205.001]

[Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]

[Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]

[Cites] Sao Paulo Med J. 2003 May 5;121(3):128-32 [12920476.001]

[Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]

[Cites] Int J Cancer. 1990 Aug 15;46(2):203-6 [2166709.001]

[Cites] Eur J Cancer. 2002 Nov;38(17):2229-42 [12441259.001]

[Cites] Br J Cancer. 1997;76(10):1271-8 [9374370.001]

[Cites] Acta Cytol. 1997 Jul-Aug;41(4):1167-70 [9250316.001]

[Cites] Cancer Lett. 1998 Jan 16;123(1):47-52 [9461017.001]

[Cites] Mod Pathol. 2003 Jul;16(7):692-9 [12861066.001]

[Cites] J Clin Microbiol. 1990 Dec;28(12):2739-43 [2177751.001]

[Cites] J Med Microbiol. 2004 Feb;53(Pt 2):125-8 [14729933.001]

[Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):173-8 [10067816.001]

[Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]

[Cites] Cytopathology. 2005 Feb;16(1):13-21 [15859310.001]

[Cites] Mod Pathol. 1995 Apr;8(3):270-4 [7617653.001]

[Cites] Scand J Infect Dis. 1996;28(6):629-32 [9060069.001]

[Cites] Dis Colon Rectum. 1987 May;30(5):345-51 [3568924.001]

[Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]

[Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]

[Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]

[Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]

[Cites] Cancer. 2004 Feb 25;102(1):19-26 [14968414.001]

[Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]

[Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]

[Cites] Dtsch Med Wochenschr. 2003 Sep 19;128(38):1957-62 [14502448.001]

[Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]

[Cites] Cancer. 1995 Feb 15;75(4):958-67 [7842416.001]

[Cites] Cancer. 2003 Apr 25;99(2):113-7 [12704691.001]

[Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]

(PMID = 15864603.001).

[ISSN] 0179-1958

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / DNA, Viral

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiation therapy advances for treatment of anal cancer.

Radiation therapy (RT) is established as the primary treatment of squamous cell carcinoma of the anus.

[MeSH-major] Anus Neoplasms / radiotherapy

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20064294.001).

[ISSN] 1540-1405

[Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN

[ISO-abbreviation] J Natl Compr Canc Netw

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 39

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-major] Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / pharmacokinetics. Carcinoma, Squamous Cell / metabolism. Chelating Agents / chemistry. Deferoxamine / analogs & derivatives. Isothiocyanates / chemistry. Positron-Emission Tomography / methods. Radioisotopes / pharmacokinetics. Zirconium / pharmacokinetics

[MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Isotope Labeling / methods. Metabolic Clearance Rate. Mice. Mice, Nude. Organ Specificity. Radioimmunodetection / methods. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution

Hazardous Substances Data Bank. DESFERRIOXAMINE .

Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Nucl Med. 2003 Aug;44(8):1271-81 [12902418.001]

[Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45 [16832633.001]

[Cites] J Nucl Med. 2003 Oct;44(10):1663-70 [14530484.001]

[Cites] Mol Imaging. 2003 Jul;2(3):131-7 [14649056.001]

[Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):155-63 [15186595.001]

[Cites] Cancer. 1972 Jan;29(1):117-21 [4332311.001]

[Cites] J Nucl Med. 1982 Oct;23(10):909-14 [7119886.001]

[Cites] J Immunol Methods. 1984 Aug 3;72(1):77-89 [6086763.001]

[Cites] Anal Biochem. 1984 Oct;142(1):68-78 [6440451.001]

[Cites] Cancer Res. 1988 Mar 1;48(5):1189-94 [3422590.001]

[Cites] Int J Cancer. 1989 Jun 15;43(6):1188-94 [2786509.001]

[Cites] Cancer Res. 1993 Sep 15;53(18):4383-90 [8364934.001]

[Cites] Cancer Res. 1995 Feb 15;55(4):878-84 [7850803.001]

[Cites] J Nucl Med. 1996 Feb;37(2):352-62 [8667076.001]

[Cites] J Nucl Med. 1996 Aug;37(8):1384-8 [8708780.001]

[Cites] J Nucl Med. 1997 Jan;38(1):112-8 [8998164.001]

[Cites] Int J Cancer. 1997 May 2;71(3):410-5 [9139877.001]

[Cites] J Nucl Med. 2005 Nov;46(11):1898-906 [16269605.001]

[Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2133-40 [16609026.001]

[Cites] Nat Rev Immunol. 2006 May;6(5):343-57 [16622479.001]

[Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]

[Cites] Phys Med Biol. 2007 Mar 7;52(5):1505-26 [17301468.001]

[Cites] J Nucl Med. 2007 Aug;48(8):1313-9 [17631557.001]

[Cites] Oncologist. 2007 Dec;12(12):1379-89 [18165614.001]

[Cites] Adv Drug Deliv Rev. 2008 Sep15;60(12):1347-70 [18538888.001]

[Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67 [18491091.001]

[Cites] J Nucl Med. 2009 Jan;50(1):2-5 [19091888.001]

[Cites] Bioconjug Chem. 2009 May 20;20(5):825-41 [19125647.001]

[Cites] Cancer Biother Radiopharm. 2003 Aug;18(4):655-61 [14503961.001]

(PMID = 19763566.001).

[ISSN] 1619-7089

[Journal-full-title] European journal of nuclear medicine and molecular imaging

[ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / 4-isothiocyanatobenzyl-desferrioxamine; 0 / Antibodies, Monoclonal; 0 / Chelating Agents; 0 / Isothiocyanates; 0 / Radioisotopes; 0 / Radiopharmaceuticals; C6V6S92N3C / Zirconium; J06Y7MXW4D / Deferoxamine

[Other-IDs] NLM/ PMC2816257

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males.

PURPOSE: The incidence of anal squamous carcinoma in males who have sex with males is rising.

We reported that infrared coagulation of high-grade squamous intraepithelial lesions in HIV-positive males who have sex with males yielded a recurrence rate after the first ablation of 65 percent and 58 percent after a second ablation.

METHODS: We performed a retrospective review of medical records on HIV-negative males who have sex with males who had infrared coagulation ablation of anal high-grade squamous intraepithelial lesions.

Recurrent high-grade squamous intraepithelial lesions were retreated.

HIV-positive patients were twice as likely to have lesions persist and 1.7 times more likely to develop a recurrent high-grade squamous intraepithelial lesion.

No patient developed squamous-cell carcinoma, anal stenosis, or had a serious complication.

CONCLUSIONS: Infrared coagulation is a safe and effective office-based procedure for treating anal high-grade squamous intraepithelial lesions.

Although recurrence was high after the first infrared coagulation, repeated treatment led to resolution of high-grade squamous intraepithelial lesions.

[MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. HIV Seronegativity. Homosexuality, Male. Infrared Rays / therapeutic use. Light Coagulation / methods. Precancerous Conditions / surgery

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Anal Cancer.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17380365.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

No evidence of a correlation was found between adduct levels in normal tissues and primary tumor biopsies.

[MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / radiotherapy. Humans. Leukocyte Count. Mouth Mucosa / cytology. Predictive Value of Tests

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Cancer. 1999 Jan;79(1):82-8 [10408697.001]

[Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]

[Cites] Int J Cancer. 2006 Aug 15;119(4):750-6 [16550603.001]

[Cites] Anal Biochem. 1999 Nov 1;275(1):30-8 [10542106.001]

[Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]

[Cites] Int J Cancer. 2000 Mar 20;89(2):160-6 [10754494.001]

[Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]

[Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]

[Cites] Clin Cancer Res. 2002 Sep;8(9):2992-9 [12231546.001]

[Cites] Clin Pharmacol Ther. 2003 May;73(5):417-26 [12732842.001]

[Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]

[Cites] Eur J Cancer Clin Oncol. 1986 Mar;22(3):257-63 [3709595.001]

[Cites] Radiother Oncol. 1986 May;6(1):61-74 [3715061.001]

[Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Nov;50(5):871-84 [3490450.001]

[Cites] Cancer Res. 1987 Jun 1;47(11):3000-4 [3552211.001]

[Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5024-8 [3110781.001]

[Cites] Cancer Res. 1987 Nov 15;47(22):6134-7 [3664513.001]

[Cites] Carcinogenesis. 1988 Oct;9(10):1909-11 [2458857.001]

[Cites] Cancer Res. 1990 Jun 15;50(12):3556-61 [2340504.001]

[Cites] Cancer Res. 1990 Dec 15;50(24):7887-94 [2253228.001]

[Cites] Cancer. 1991 Jun 1;67(11):2828-32 [2025848.001]

[Cites] Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):612-7 [8499090.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):229-34 [8318875.001]

[Cites] Cancer Res. 1993 Dec 1;53(23):5669-75 [8242622.001]

[Cites] Cancer. 1994 Jun 1;73(11):2843-52 [7514956.001]

[Cites] Br J Cancer. 1995 Mar;71(3):512-7 [7880732.001]

[Cites] Carcinogenesis. 1995 Oct;16(10):2447-53 [7586150.001]

[Cites] Cancer Chemother Pharmacol. 1995;37(1-2):23-31 [7497593.001]

[Cites] Cancer Chemother Pharmacol. 1995;37(1-2):150-4 [7497585.001]

[Cites] Br J Cancer. 1996 Jun;73(12):1569-75 [8664132.001]

[Cites] Int J Cancer. 1996 Nov 15;68(4):452-6 [8945615.001]

[Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]

[Cites] Clin Cancer Res. 1996 Jun;2(6):1063-6 [9816268.001]

[Cites] Clin Cancer Res. 1996 Nov;2(11):1829-35 [9816137.001]

[Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]

[Cites] Int J Cancer. 2006 Apr 15;118(8):1963-71 [16287073.001]

(PMID = 17639394.001).

[ISSN] 0344-5704

[Journal-full-title] Cancer chemotherapy and pharmacology

[ISO-abbreviation] Cancer Chemother. Pharmacol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; Q20Q21Q62J / Cisplatin

[Other-IDs] NLM/ PMC2270367

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This fluorescent molecular probe consists of a thiol reaction moiety bound to a coumarin fluorophore.

[MeSH-major] Carcinoma, Squamous Cell / chemistry. Fluorescent Dyes / chemistry. Sulfhydryl Compounds / analysis. Tongue Neoplasms / chemistry

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Am Chem Soc. 2003 Jul 2;125(26):7802-3 [12822989.001]

[Cites] Clin Chem. 1990 Dec;36(12):2137-8 [2253363.001]

[Cites] Chem Commun (Camb). 2009 Aug 14;(30):4530-2 [19617973.001]

[Cites] J Am Chem Soc. 2007 Aug 29;129(34):10322-3 [17672463.001]

[Cites] Angew Chem Int Ed Engl. 2005 May 6;44(19):2922-5 [15818626.001]

[Cites] Org Lett. 2008 Jan 3;10(1):37-40 [18062694.001]

[Cites] Anal Biochem. 2007 Dec 1;371(1):71-81 [17727809.001]

[Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2001 Oct;57(12):2403-7 [11767834.001]

[Cites] J Pharm Biomed Anal. 2008 Dec 15;48(5):1375-80 [18926658.001]

[Cites] N Engl J Med. 1997 Jul 24;337(4):230-6 [9227928.001]

[Cites] Anal Chim Acta. 2008 Jul 14;620(1-2):120-6 [18558132.001]

[Cites] Chem Commun (Camb). 2003 Jan 7;(1):146-7 [12611008.001]

[Cites] Bioelectrochemistry. 2004 Jun;63(1-2):19-24 [15110242.001]

[Cites] Angew Chem Int Ed Engl. 2008;47(41):7883-7 [18781571.001]

[Cites] Anal Chem. 2007 Nov 15;79(22):8769-73 [17924649.001]

[Cites] Anal Chem. 2000 Dec 1;72(23):5755-60 [11128932.001]

[Cites] Cancer Lett. 2004 May 28;208(2):143-53 [15142672.001]

[Cites] Org Lett. 2009 Nov 5;11(21):4918-21 [19788282.001]

[Cites] Chem Commun (Camb). 2004 Aug 7;(15):1762-3 [15278174.001]

[Cites] Angew Chem Int Ed Engl. 2009;48(22):4034-7 [19388016.001]

[Cites] Org Lett. 2007 Aug 16;9(17 ):3375-7 [17645349.001]

[Cites] Bioorg Med Chem Lett. 2008 Apr 1;18(7):2246-9 [18358719.001]

[Cites] Clin Chem. 1998 Aug;44(8 Pt 2):1833-43 [9702993.001]

[Cites] J Nutr. 2006 Jun;136(6 Suppl):1682S-1693S [16702340.001]

[Cites] N Engl J Med. 2002 Feb 14;346(7):476-83 [11844848.001]

[Cites] J Chromatogr. 1985 Feb 27;338(1):209-12 [4019645.001]

[Cites] Anal Chem. 2001 Dec 15;73(24):5972-8 [11791568.001]

[Cites] Anal Chem. 2002 Mar 15;74(6):1349-54 [11922303.001]

[Cites] Eur J Biochem. 2000 Aug;267(16):4904-11 [10931172.001]

[Cites] Talanta. 2003 Aug 29;60(6):1229-38 [18969150.001]

[Cites] J Fluoresc. 2009 Jul;19(4):593-9 [19050997.001]

[Cites] Neurosci Lett. 1990 Mar 2;110(1-2):216-20 [2325885.001]

[Cites] Amino Acids. 2009 Jul;37(2):395-400 [18695935.001]

[Cites] Chem Commun (Camb). 2005 Jul 7;(25):3189-91 [15968367.001]

[Cites] Chemistry. 2009;15(20):5096-103 [19343759.001]

[Cites] Anal Chim Acta. 2008 Oct 10;627(2):254-7 [18809081.001]

[Cites] J Clin Invest. 1960 Nov;39(11):1633-8 [16695834.001]

(PMID = 20473559.001).

[ISSN] 1573-4994

[Journal-full-title] Journal of fluorescence

[ISO-abbreviation] J Fluoresc

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Sulfhydryl Compounds

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.

Human papilloma virus (HPV) infection is considered as an important aetiological factor for anal squamous cell carcinoma (ASCC) but is not sufficient for tumour progression.

This carcinoma is poorly understood at the molecular level.

[MeSH-major] Anus Neoplasms / genetics. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Mutation. Papillomaviridae / isolation & purification. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Tumor Suppressor Protein p53 / genetics

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 17721920.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: Between 1989 and 1998, 46 patients underwent pelvi-perineal reconstruction with RAM flaps after radical pelvic surgery for carcinoma of the cervix (n=22), anal carcinoma (n=11), rectal carcinoma (n=7), or other pelvic tumours types (n=6).

MedlinePlus Health Information. consumer health - Surgery.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16126359.001).

[ISSN] 0748-7983

[Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

[ISO-abbreviation] Eur J Surg Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Binding of IRDye 800CW EGF to intact A431 human epidermoid carcinoma cells was quantified in a microplate assay.

This is the first study to directly correlate targeting agent signal strength in whole cell binding, In-Cell Western, and in vivo near-infrared imaging.

[MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epidermal Growth Factor

[MeSH-minor] Animals. Cell Line, Tumor. Chromatography, Gel. Chromatography, High Pressure Liquid. Coloring Agents. Humans. Indicators and Reagents. Mice. Mice, Nude. Mice, SCID. Receptor, Epidermal Growth Factor. Sensitivity and Specificity. Spectrometry, Fluorescence / methods. Transplantation, Heterologous

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):600-14 [12154371.001]

[Cites] Am J Pathol. 2002 Sep;161(3):849-57 [12213713.001]

[Cites] Amino Acids. 2002;23(1-3):301-8 [12373551.001]

[Cites] Clin Cancer Res. 2002 Nov;8(11):3438-44 [12429632.001]

[Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S9-14 [12867057.001]

[Cites] Curr Opin Chem Biol. 2003 Oct;7(5):626-34 [14580568.001]

[Cites] Cancer Res. 2003 Nov 15;63(22):7870-5 [14633715.001]

[Cites] Mol Imaging. 2003 Oct;2(4):303-12 [14717329.001]

[Cites] Nat Biotechnol. 2004 Feb;22(2):198-203 [14704683.001]

[Cites] Mol Cancer Ther. 2004 Apr;3(4):481-8 [15078992.001]

[Cites] Mol Imaging. 2004 Jan;3(1):9-23 [15142408.001]

[Cites] Science. 1977 Dec 23;198(4323):1264-7 [929199.001]

[Cites] EMBO J. 1987 Mar;6(3):605-10 [3034598.001]

[Cites] Am J Pathol. 2006 Oct;169(4):1415-26 [17003496.001]

[Cites] Nat Biotechnol. 2001 Apr;19(4):327-31 [11283589.001]

[Cites] Nat Biotechnol. 2005 Mar;23(3):313-20 [15765087.001]

[Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]

[Cites] Anal Biochem. 2005 Mar 1;338(1):136-42 [15707944.001]

[Cites] Cancer Res. 2004 Nov 1;64(21):8009-14 [15520209.001]

[Cites] Biochemistry. 1993 Nov 16;32(45):12039-45 [8218281.001]

[Cites] Curr Opin Oncol. 1993 May;5(3):474-80 [8494908.001]

[Cites] Annu Rev Biophys Biophys Chem. 1991;20:1-28 [1867711.001]

[Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]

[Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1433-41 [16287239.001]

[Cites] Mol Imaging. 2005 Oct-Dec;4(4):439-47 [16285906.001]

[Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41205 [16178629.001]

[Cites] Drugs Today (Barc). 2005 Feb;41(2):107-27 [15821783.001]

(PMID = 17188228.001).

[ISSN] 0003-2697

[Journal-full-title] Analytical biochemistry

[ISO-abbreviation] Anal. Biochem.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA106584

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Coloring Agents; 0 / Indicators and Reagents; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

[Other-IDs] NLM/ NIHMS16673; NLM/ PMC1866276

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Cancer incidence rates were race specific and were adjusted for age; these were compared with national rates using logistic regression to assess predictors of NADC development.

The most frequent NADCs were skin carcinomas (basal cell and squamous cell), Hodgkin disease, and anal carcinoma.

The results showed that there were higher rates of melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease among the HIV-infected cohort compared with age-adjusted rates for the general United States population.

A low CD4 nadir or CD4 count at diagnosis (< 200 cells/mL) was not predictive of NADCs.

CONCLUSIONS: The most frequent NADCs were primary skin malignancies.

Melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease occurred at higher rates among HIV-infected individuals.

[MeSH-minor] Adult. Age Distribution. Aged. Analysis of Variance. Cohort Studies. Comorbidity. Female. HIV Infections / diagnosis. HIV Infections / epidemiology. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Probability. Prognosis. Retrospective Studies. Risk Factors. Severity of Illness Index. Sex Distribution. Survival Analysis. United States / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16104038.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling.

Shotgun proteomics provides the most powerful analytical platform for global inventory of complex proteomes using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and allows a global analysis of protein changes.

Nevertheless, sampling of complex proteomes by current shotgun proteomics platforms is incomplete, and this contributes to variability in assessment of peptide and protein inventories by spectral counting approaches.

Thus, shotgun proteomics data pose challenges in comparing proteomes from different biological states.

We developed an analysis strategy using quasi-likelihood Generalized Linear Modeling (GLM), included in a graphical interface software package (QuasiTel) that reads standard output from protein assemblies created by IDPicker, an HTML-based user interface to query shotgun proteomic data sets.

This approach was compared to four other statistical analysis strategies: Student t test, Wilcoxon rank test, Fisher's Exact test, and Poisson-based GLM.

We analyzed the performance of these tests to identify differences in protein levels based on spectral counts in a shotgun data set in which equimolar amounts of 48 human proteins were spiked at different levels into whole yeast lysates.

Both GLM approaches and the Fisher Exact test performed adequately, each with their unique limitations.

We subsequently compared the proteomes of normal tonsil epithelium and HNSCC using this approach and identified 86 proteins with differential spectral counts between normal tonsil epithelium and HNSCC.

We selected 18 proteins from this comparison for verification of protein levels between the individual normal and tumor tissues using liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS).

This analysis confirmed the magnitude and direction of the protein expression differences in all 6 proteins for which reliable data could be obtained.

Our analysis demonstrates that shotgun proteomic data sets from different tissue phenotypes are sufficiently rich in quantitative information and that statistically significant differences in proteins spectral counts reflect the underlying biology of the samples.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biometrics. 2001 Jun;57(2):620-4 [11414592.001]

[Cites] J Proteome Res. 2010 Feb 5;9(2):761-76 [19921851.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]

[Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]

[Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]

[Cites] Anal Chem. 2002 Jul 1;74(13):3076-83 [12141667.001]

[Cites] Dis Markers. 2002;18(2):99-105 [12364816.001]

[Cites] Nat Biotechnol. 2003 Mar;21(3):262-7 [12610573.001]

[Cites] J Proteome Res. 2003 Nov-Dec;2(6):643-9 [14692458.001]

[Cites] Am J Pathol. 2004 Jan;164(1):35-42 [14695316.001]

[Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]

[Cites] Bioinformatics. 2004 Aug 4;20 Suppl 1:i31-9 [15262778.001]

[Cites] Nat Biotechnol. 2004 Aug;22(8):985-92 [15258593.001]

[Cites] Biometrics. 1991 Jun;47(2):383-401 [1912253.001]

[Cites] J Invest Dermatol. 1992 Sep;99(3):299-305 [1512466.001]

[Cites] Biochem J. 1994 Sep 1;302 ( Pt 2):363-71 [8092987.001]

[Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):871-6 [8634660.001]

[Cites] J Invest Dermatol. 1997 Feb;108(2):200-4 [9008234.001]

[Cites] Cancer Lett. 2005 Jul 8;225(1):151-7 [15922867.001]

[Cites] Anal Chem. 2005 Oct 1;77(19):6218-24 [16194081.001]

[Cites] Mol Cell Proteomics. 2005 Oct;4(10):1487-502 [15979981.001]

[Cites] Nat Biotechnol. 2006 Aug;24(8):971-83 [16900146.001]

[Cites] J Proteome Res. 2006 Nov;5(11):2909-18 [17081042.001]

[Cites] BMC Genomics. 2006;7:278 [17074082.001]

[Cites] Cardiovasc Res. 2007 Jan 1;73(1):19-25 [17045254.001]

[Cites] J Proteome Res. 2007 Feb;6(2):654-61 [17269722.001]

[Cites] J Proteome Res. 2007 Sep;6(9):3549-57 [17676885.001]

[Cites] J Proteome Res. 2007 Oct;6(10):3962-75 [17711321.001]

[Cites] J Proteome Res. 2008 Mar;7(3):845-54 [18198819.001]

[Cites] Mol Cell Proteomics. 2008 Dec;7(12):2373-85 [18644780.001]

[Cites] J Proteome Res. 2008 Dec;7(12):5286-94 [18939861.001]

[Cites] Proteomics. 2009 Apr;9(8):2193-201 [19337991.001]

[Cites] Nat Biotechnol. 2009 Jul;27(7):633-41 [19561596.001]

[Cites] J Oral Pathol Med. 2009 Jul;38(6):530-4 [19222712.001]

[Cites] J Proteome Res. 2009 Aug;8(8):3872-81 [19522537.001]

[Cites] Bioinformatics. 2010 Feb 1;26(3):363-9 [20007255.001]

[Cites] Mol Cell Proteomics. 2010 Feb;9(2):242-54 [19858499.001]

[ErratumIn] J Proteome Res. 2010 Nov 5;9(11):6090

(PMID = 20586475.001).

[ISSN] 1535-3907

[Journal-full-title] Journal of proteome research

[ISO-abbreviation] J. Proteome Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U24 CA126479; United States / NCI NIH HHS / CA / 1U24CA126479

[Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Proteins

[Other-IDs] NLM/ PMC2920032

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epidermal growth factor receptor expression in anal canal carcinoma.

Most anal canal carcinomas (ACCs) are squamous cell carcinomas (SCCs).

Therefore, we obtained archived pathology samples from ACC biopsies and examined the frequency and level of expression of EGFR and other cell surface and cell cycle markers.

[MeSH-major] Anal Canal / pathology. Anus Neoplasms / metabolism. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Receptor, Epidermal Growth Factor / biosynthesis

MedlinePlus Health Information. consumer health - Anal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15923158.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-major] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Receptor, PAR-2 / metabolism. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology

MedlinePlus Health Information. consumer health - Cervical Cancer.

International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Oncol. 2003 Jul;23(1):61-6 [12792776.001]

[Cites] J Histochem Cytochem. 1998 Feb;46(2):157-64 [9446822.001]

[Cites] J Biol Chem. 2004 May 14;279(20):20927-34 [15010475.001]

[Cites] Int J Oncol. 2004 Jun;24(6):1401-6 [15138580.001]

[Cites] Mol Cancer Res. 2004 Jul;2(7):395-402 [15280447.001]

[Cites] Oncol Rep. 2004 Nov;12(5):1013-6 [15492786.001]

[Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]

[Cites] Cancer. 1986 Apr 15;57(8):1584-93 [2418947.001]

[Cites] J Cell Biol. 2000 Mar 20;148(6):1267-81 [10725339.001]

[Cites] J Neural Transm (Vienna). 2001;108(2):125-40 [11314768.001]

[Cites] Pharmacol Rev. 2001 Jun;53(2):245-82 [11356985.001]

[Cites] Am J Pathol. 2001 Jun;158(6):2031-41 [11395381.001]

[Cites] Br J Cancer. 2001 Sep 1;85(5):772-9 [11531266.001]

[Cites] Life Sci. 2002 Feb 8;70(12):1359-67 [11883712.001]

[Cites] FEBS Lett. 2002 Jul 17;523(1-3):85-9 [12123809.001]

[Cites] Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1421-6 [12231560.001]

[Cites] Cancer. 2003 Feb 1;97(3):703-13 [12548614.001]

[Cites] Gynecol Oncol. 1987 Jun;27(2):150-8 [3570054.001]

[Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]

[Cites] Semin Diagn Pathol. 1990 Aug;7(3):173-89 [2218146.001]

[Cites] Cancer Metastasis Rev. 1992 Mar;11(1):31-44 [1511495.001]

[Cites] Gynecol Oncol. 1998 May;69(2):157-64 [9600824.001]

[Cites] Int J Pancreatol. 1998 Oct;24(2):97-102 [9816542.001]

[Cites] Cancer Lett. 1999 May 3;139(1):109-13 [10408902.001]

[Cites] Cancer Res. 2006 Jan 1;66(1):307-14 [16397244.001]

[Cites] J Surg Oncol. 2006 Feb 1;93(2):139-44 [16425301.001]

[Cites] Am J Pathol. 2006 Jul;169(1):268-78 [16816379.001]

[Cites] J Biol Chem. 2000 Feb 18;275(7):4592-8 [10671485.001]

[Cites] Eur J Biochem. 1995 Aug 15;232(1):84-9 [7556175.001]

[Cites] Biochem J. 1996 Mar 15;314 ( Pt 3):1009-16 [8615752.001]

[Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):437-42 [12966163.001]

(PMID = 18937843.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, PAR-2

[Other-IDs] NLM/ PMC2587477

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.

Chemoradiotherapy (CRT) is accepted as the standard initial treatment for squamous cell anal cancer.

This paper reports the results of a modified regimen for this group of patients.

In all, 16 patients with biopsy-proven squamous cell carcinoma of the anal canal or margin and performance status or co-morbidity precluding the use of full-dose CRT were included in this protocol.

Patients received a dose of 30 Gy to the gross tumour volume plus 3 cm margin in all directions.

Only one patient experienced any grade 3 toxicity (skin).

This is a well-tolerated regimen for elderly/poor performance patients with anal cancer, which can achieve high rates of local control and survival.

[MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Fluorouracil / therapeutic use. Frail Elderly

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

Hazardous Substances Data Bank. FLUOROURACIL .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):65-9 [12118566.001]

[Cites] Cancer. 1997 Oct 15;80(8):1387-92 [9338461.001]

[Cites] J Clin Oncol. 2004 Aug 1;22(15):2978-81 [15210736.001]

[Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]

[Cites] Nephron. 1976;16(1):31-41 [1244564.001]

[Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]

[Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82 [7172946.001]

[Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]

[Cites] Radiother Oncol. 1985 Feb;3(2):145-50 [3920734.001]

[Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]

[Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]

[Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]

[Cites] Cancer. 1993 Mar 1;71(5):1736-40 [8448738.001]

[Cites] Radiology. 1994 May;191(2):569-72 [8153343.001]

[Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]

[Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]

[Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]

[Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]

[Cites] Br J Cancer. 2003 May 6;88(9):1352-7 [12778060.001]

(PMID = 15798772.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2361984

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men.

Due to the increasing incidence of anal cancer in HIV-positive men who have sex with men, and the potential to detect and treat high-grade anal dysplasia--the putative anal cancer precursor--we have introduced an anal cytology screening service.

Patients with abnormal anal cytology have follow-up high-resolution anoscopy (HRA) with biopsy of lesions clinically suspicious for high-grade dysplasia.

One hundred and sixty-four (67%) men had abnormal anal cytology, and 93 of them had follow-up HRA and anal biopsy.

The positive predictive value for any anal cytological abnormality to predict any degree of anal dysplasia was 95.7+/-2.1%, and for any anal cytological abnormality to predict high-grade anal dysplasia was 55.9+/-5.1%.

Abnormal anal cytology was highly predicative of anal dysplasia on biopsy.

[MeSH-major] Anal Canal / pathology. Anus Neoplasms. Carcinoma, Squamous Cell. HIV Infections / complications. Homosexuality, Male

[MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / epidemiology. Adult. Aged. Biopsy. Cytological Techniques. Humans. Male. Middle Aged. Predictive Value of Tests. Prevalence

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - HIV/AIDS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17331275.001).

[ISSN] 0956-4624

[Journal-full-title] International journal of STD & AIDS

[ISO-abbreviation] Int J STD AIDS

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Cluster analysis was applied to find any relationship between spectral shape and lesion type or cell layer.

No clustering with regard to lesion type or cell layer was observed.

Raman spectra allowed for reliable classification into cell layers, but differences between lesion types were not significant in this study.

[MeSH-minor] Carcinoma, Squamous Cell / pathology. Cluster Analysis. Connective Tissue / pathology. Epithelium / pathology. Freeze Drying. Humans. Keratins / metabolism. Mouth Neoplasms / pathology

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):279-96 [12916660.001]

[Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]

[Cites] J Biomed Opt. 2001 Jan;6(1):41-51 [11178579.001]

[Cites] Int J Cancer. 2003 Dec 20;107(6):1047-52 [14601068.001]

[Cites] Lasers Surg Med. 1992;12(1):63-78 [1614265.001]

[Cites] Photochem Photobiol. 1998 Jul;68(1):123-32 [9679458.001]

[Cites] J Invest Dermatol. 2002 Jul;119(1):64-9 [12164926.001]

[Cites] Am J Obstet Gynecol. 2002 Mar;186(3):374-82 [11904594.001]

[Cites] Gastrointest Endosc. 2003 Mar;57(3):396-402 [12612529.001]

[Cites] J Biomed Opt. 2004 Sep-Oct;9(5):940-50 [15447015.001]

[Cites] Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1630-5 [11597937.001]

[Cites] Photochem Photobiol. 1997 Oct;66(4):418-23 [9337612.001]

[Cites] Photochem Photobiol. 1996 May;63(5):662-71 [8628758.001]

[Cites] J Am Paraplegia Soc. 1994 Oct;17(4):161-4 [7869057.001]

[Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]

[Cites] Head Neck. 1998 Sep;20(6):556-62 [9702544.001]

[Cites] Anal Chem. 2000 Dec 15;72(24):6010-8 [11140770.001]

[Cites] Br J Cancer. 2003 Jul 7;89(1):106-8 [12838309.001]

[Cites] Technol Cancer Res Treat. 2003 Aug;2(4):327-32 [12892515.001]

[Cites] Biopolymers. 2001;62(4):185-92 [11391568.001]

(PMID = 15772873.001).

[ISSN] 0268-8921

[Journal-full-title] Lasers in medical science

[ISO-abbreviation] Lasers Med Sci

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 68238-35-7 / Keratins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Raman spectroscopy in head and neck cancer.

In recent years there has been much interest in the use of optical diagnostics in cancer detection.

Early diagnosis of cancer affords early intervention and greatest chance of cure.

Raman has been used successfully in key health areas such as cardiovascular diseases, and dental care but there is a paucity of literature on Raman spectroscopy in Head and Neck cancer.

Following the introduction of health care targets for cancer, and with an ever-aging population the need for rapid cancer detection has never been greater.

Raman spectroscopy could confer great patient benefit with early, rapid and accurate diagnosis.

It could reduce the need for whole pathological specimen examination, in theatre it could help to determine margin status, and finally peripheral blood diagnosis may be an achievable target.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]

[Cites] Eur J Med Res. 2010 Mar 30;15(3):131-4 [20452899.001]

[Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1756-63 [11037840.001]

[Cites] Br J Dermatol. 2002 Mar;146(3):448-57 [11952545.001]

[Cites] J Biomed Opt. 2003 Jan;8(1):121-47 [12542388.001]

[Cites] Lasers Surg Med. 2003;32(3):210-4 [12605428.001]

[Cites] Gastrointest Endosc. 2003 Mar;57(3):396-402 [12612529.001]

[Cites] Photochem Photobiol. 2003 Aug;78(2):197-204 [12945589.001]

[Cites] Anal Chem. 2003 Dec 1;75(23):6679-86 [14640745.001]

[Cites] J Invest Dermatol. 2004 Feb;122(2):443-9 [15009728.001]

[Cites] Gynecol Oncol. 2004 Apr;93(1):59-68 [15047215.001]

[Cites] J Cell Biochem. 2004 Aug 15;92(6):1180-92 [15258901.001]

[Cites] Bioinformatics. 2005 Apr 1;21(7):860-8 [15513990.001]

[Cites] Lasers Surg Med. 2005 Sep;37(3):192-200 [16127671.001]

[Cites] Biopolymers. 2006 Feb 15;81(3):179-93 [16231284.001]

[Cites] Oral Oncol. 2006 Mar;42(3):221-8 [16140566.001]

[Cites] Cancer Res. 2006 Mar 15;66(6):3317-22 [16540686.001]

[Cites] J Biomed Opt. 2006 Mar-Apr;11(2):021003 [16674178.001]

[Cites] Bioinformatics. 2006 Oct 15;22(20):2565-6 [16882648.001]

[Cites] Biochem Soc Trans. 2007 Jun;35(Pt 3):544-9 [17511648.001]

[Cites] Int J Nanomedicine. 2007;2(4):785-98 [18203445.001]

[Cites] Analyst. 2008 Oct;133(10):1416-23 [18810290.001]

[Cites] Biopolymers. 2009 Jul;91(7):539-46 [19226625.001]

[Cites] Head Neck Oncol. 2009;1:25 [19594907.001]

[Cites] Head Neck Oncol. 2009;1:34 [19761601.001]

[Cites] Head Neck Oncol. 2009;1:38 [19863815.001]

[Cites] Oral Oncol. 2009 Dec;45(12):1006-10 [19828359.001]

[Cites] Int J Gynecol Cancer. 2010 Feb;20(2):283-7 [20134271.001]

[Cites] Expert Rev Anticancer Ther. 2010 Mar;10(3):321-9 [20214513.001]

[Cites] Anal Chem. 2000 Aug 15;72(16):3771-5 [10959962.001]

(PMID = 20923567.001).

[ISSN] 1758-3284

[Journal-full-title] Head & neck oncology

[ISO-abbreviation] Head Neck Oncol

[Language] ENG

[Grant] United Kingdom / Cancer Research UK / /

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Other-IDs] NLM/ PMC2958871

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells.

However, little is known the effect of ROCK on cell adhesion and mobility in esophageal squamous cell cancer (ESCC), one of the most diagnosed cancers in China.

All these findings indicate that ROCK signaling pathway plays an important role in cell adhesion and mobility, suggesting that it may be used as a potential target for therapy of ESCC.

[MeSH-major] Amides / pharmacology. Carcinoma, Squamous Cell / pathology. Cell Movement / drug effects. Esophageal Neoplasms / pathology. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. rho-Associated Kinases / antagonists & inhibitors

[MeSH-minor] Cell Adhesion / drug effects. Cell Line, Tumor. Humans

Genetic Alliance. consumer health - Esophageal Cancer.

MedlinePlus Health Information. consumer health - Esophageal Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Hepatol Res. 2008 Aug;38(8):810-7 [18507693.001]

[Cites] Am J Physiol Cell Physiol. 2008 Jul;295(1):C38-49 [18463228.001]

[Cites] Exp Cell Res. 2008 Oct 15;314(17):3162-74 [18694745.001]

[Cites] Mol Cancer Res. 2008 Sep;6(9):1410-20 [18819929.001]

[Cites] World J Gastroenterol. 2008 May 21;14(19):3054-8 [18494058.001]

[Cites] J Craniomaxillofac Surg. 2007 Jan;35(1):1-9 [17296306.001]

[Cites] Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5549-57 [18055804.001]

[Cites] Am J Physiol Cell Physiol. 2006 Oct;291(4):C668-77 [16641163.001]

[Cites] Am J Respir Cell Mol Biol. 1999 Jun;20(6):1190-200 [10340938.001]

[Cites] Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3317-25 [12882776.001]

[Cites] Ann N Y Acad Sci. 2005 Nov;1056:405-12 [16387705.001]

[Cites] J Biol Chem. 2009 May 29;284(22):15147-57 [19293150.001]

[Cites] Int J Oncol. 2008 Sep;33(3):585-93 [18695890.001]

[Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]

[Cites] J Pharmacol Exp Ther. 2008 Dec;327(3):777-88 [18791066.001]

[Cites] World J Gastroenterol. 2008 Oct 7;14(37):5665-73 [18837082.001]

[Cites] Acta Biochim Biophys Sin (Shanghai). 2006 May;38(5):318-26 [16680372.001]

[Cites] Neoplasia. 2008 Dec;10(12):1444-58 [19048123.001]

[Cites] Jpn J Cancer Res. 2000 Aug;91(8):811-6 [10965022.001]

[Cites] J Cell Biol. 2008 Nov 17;183(4):697-710 [19015318.001]

[Cites] Cancer Lett. 2009 Nov 1;284(2):122-30 [19303207.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11305-10 [18685096.001]

[Cites] Cancer Lett. 2007 Aug 18;253(2):236-48 [17360108.001]

[Cites] Gut. 2009 Aug;58(8):1121-7 [19398441.001]

[Cites] Biol Pharm Bull. 2008 Sep;31(9):1802-5 [18758081.001]

[Cites] Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1500-9 [16565385.001]

[Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]

[Cites] J Pineal Res. 2009 Jan;46(1):15-21 [18482340.001]

[Cites] Kobe J Med Sci. 2007;53(3):125-34 [17684444.001]

[Cites] Mol Cancer Res. 2005 Aug;3(8):425-33 [16123138.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] Histopathology. 2008 Apr;52(5):560-8 [18312357.001]

[Cites] J Biol Chem. 2006 Oct 6;281(40):29614-24 [16882662.001]

[Cites] Lab Invest. 2007 Nov;87(11):1149-58 [17876296.001]

[Cites] Cancer Lett. 2005 Jan 31;218(1):69-79 [15639342.001]

(PMID = 19649725.001).

[ISSN] 1573-4978

[Journal-full-title] Molecular biology reports

[ISO-abbreviation] Mol. Biol. Rep.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Amides; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 138381-45-0 / Y 27632; EC 2.7.11.1 / rho-Associated Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-major] Biomarkers, Tumor / analysis. Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Tenascin / analysis

MedlinePlus Health Information. consumer health - Biopsy.

MedlinePlus Health Information. consumer health - Oral Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]

[Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):986-90 [15094113.001]

[Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]

[Cites] Int J Mol Med. 2000 May;5(5):505-10 [10762653.001]

[Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]

[Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]

[Cites] J Oral Pathol Med. 2006 Sep;35(8):520; author reply 520-2 [16918607.001]

[Cites] Int J Cancer. 2002 Aug 20;100(6):719-22 [12209613.001]

[Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]

[Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]

[Cites] Oncology. 2003;64(3):245-50 [12697965.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):252 [14515857.001]

[Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]

[Cites] Biochem Cell Biol. 1997;75(6):759-69 [9599665.001]

[Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]

[Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]

[Cites] Int J Cancer. 1998 Mar 2;75(5):680-7 [9495234.001]

[Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]

[Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]

[Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]

[Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]

[Cites] J Oral Pathol Med. 1994 Nov;23(10):446-50 [7532219.001]

[Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]

[Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]

[Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]

[Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]

[Cites] Oral Oncol. 2002 Jun;38(4):332-6 [12076695.001]

[Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]

[Cites] Gen Dent. 2002 Nov-Dec;50(6):500-3 [12572180.001]

[Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]

(PMID = 17111122.001).

[ISSN] 1432-6981

[Journal-full-title] Clinical oral investigations

[ISO-abbreviation] Clin Oral Investig

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Apoptotic count as a guide for histological grading of carcinoma esophagus: a light microscopic study.

AIMS: The study aims to find out if a correlation between apoptotic count and histological grading exists in squamous cell carcinoma of the esophagus, and also to review the literature on such a relationship in the context of some other tumors.

SETTINGS AND DESIGN: Cases of squamous cell carcinoma of the esophagus who presented at a tertiary care center over a period of one year were reviewed.

MATERIALS AND METHODS: The endoscopic biopsy specimens of 56 patients of squamous cell carcinoma of esophagus were fixed in 10% buffered formalin, processed for routine paraffin sections, sections taken, stained by hematoxylin and eosin and examined under light microscope, using 40× objective and 10× eyepiece.

CONCLUSIONS: Grading of squamous cell carcinoma of esophagus, solely on the basis of apoptotic count can be used in the first place or to corroborate conventional histological grading done on the basis of morphology.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anticancer Res. 2000 May-Jun;20(3B):2123-8 [10928164.001]

[Cites] Am J Surg Pathol. 1997 Jan;21(1):88-101 [8990145.001]

[Cites] Indian J Pathol Microbiol. 2001 Jul;44(3):257-9 [12024908.001]

[Cites] Surgery. 2006 Dec;140(6):899-905; discussion 905-6 [17188136.001]

[Cites] Mod Pathol. 2007 Oct;20(10):1036-44 [17643097.001]

[Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]

[Cites] Stroke. 1995 Jul;26(7):1252-7; discussion 1257-8 [7541573.001]

[Cites] Int J Cancer. 1995 Jun 9;61(6):826-31 [7790118.001]

[Cites] Arch Pathol Lab Med. 1997 Jan;121(1):54-8 [9111093.001]

[Cites] J Cell Biol. 1997 Aug 25;138(4):901-11 [9265655.001]

[Cites] Anal Quant Cytol Histol. 2002 Apr;24(2):73-80 [12026053.001]

[Cites] Int J Oral Maxillofac Surg. 2005 Dec;34(8):900-6 [15907374.001]

[Cites] Cancer Res. 1995 May 1;55(9):1811-6 [7728743.001]

[Cites] Nature. 1996 Jan 4;379(6560):19-20 [8538735.001]

[Cites] Histopathology. 1995 Nov;27(5):469-72 [8575739.001]

[Cites] Blood. 1996 Mar 15;87(6):2470-5 [8630413.001]

[Cites] Indian J Pathol Microbiol. 2000 Jul;43(3):271-5 [11218671.001]

(PMID = 21938242.001).

[ISSN] 0974-2727

[Journal-full-title] Journal of laboratory physicians

[ISO-abbreviation] J Lab Physicians

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC3167958

[Keywords] NOTNLM ; Apoptotic count / histological grading / squamous cell carcinoma esophagus

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany.

BACKGROUND: Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated potential precursor lesion of anal cancer, is frequent among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).

There is a paucity of data published on the progression of high-grade AIN to invasive cancer as well as on clinical and virological characteristics comparing anal margin and anal canal carcinoma.

OBJECTIVES: To search for anal carcinoma and AIN in a large series of HIV-positive MSM, to assess treatment response of anal carcinoma, and to analyse lesional HPV spectrum of anal cancers.

METHODS: Detection of anal carcinoma and AIN was performed using cytology, high-resolution anoscopy, and histology in case of abnormal findings.

Additionally, HPV analyses for 36 high- and low-risk α-HPV types were performed in patients with anal carcinoma.

Of these, 116 (26·0%) patients had normal findings, 163 (36·5%) had low-grade AIN, 156 (35·0%) had high-grade AIN, and 11 (2·5%) had anal carcinoma as evidenced by the highest grade of cytology/histology.

Five patients with anal cancer, who had refused treatment of their precancerous lesions, had progressed from high-grade AIN to invasive cancer within a median time of 8·6 months.

All anal cancers carried high-risk α-HPV types.

All five squamous cell carcinomas (SCCs) of the anal canal were HPV16 positive.

In contrast, only one of the four anal margin SCCs were HPV16 positive (HPV31, HPV33 and HPV33 + HPV68 were found in the other three anal margin SCCs).

In contrast to the cancer biopsies, a broad spectrum of surface high- and low-risk HPV types was found in anal swabs of the patients.

Surgical excision resulted in long-term disease control of all anal margin carcinomas, whereas combined chemoradiotherapy in carcinomas of the anal canal was associated with high recurrence rates, high toxicity, and high mortality.

CONCLUSIONS: Anal carcinoma and AIN are frequent in HIV-positive men, even in patients participating in anal cancer prevention programmes.

High-grade dysplasia in these patients can progress to invasive cancer within a short period of time.

Anal margin carcinoma and anal canal carcinoma differ substantially in their lesional HPV spectrum, prognosis and treatment response.

[MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification

MedlinePlus Health Information. consumer health - Anal Cancer.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.

(PMID = 20184584.001).

[ISSN] 1365-2133

[Journal-full-title] The British journal of dermatology

[ISO-abbreviation] Br. J. Dermatol.

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00365729

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In this regard, two novel sensitive and selective strategies are proposed here to quantify cisplatin-DNA adducts generated in Drosophila melanogaster larvae and in head and neck squamous cell carcinoma cultures.

Two different strategies, based on isotope dilution analysis (IDA), have been attempted and evaluated for quantification: species-unspecific (the postcolumn addition of a 194Pt-enriched solution) and the species-specific (by means of a synthesized isotopically enriched cisplatin (194Pt) adduct).

Species-specific spiking before enzymatic digestion provided accurate and precise analytical results to clearly differentiate between Drosophila samples and carcinoma cell cultures exposed to different cisplatin concentrations.

[MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Drosophila melanogaster / metabolism. Humans. Indicator Dilution Techniques. Isotopes. Mass Spectrometry. Oligodeoxyribonucleotides / genetics. Oligodeoxyribonucleotides / metabolism

FlyBase. FlyBase .

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19886652.001).

[ISSN] 1520-6882

[Journal-full-title] Analytical chemistry

[ISO-abbreviation] Anal. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Adducts; 0 / Isotopes; 0 / Oligodeoxyribonucleotides; Q20Q21Q62J / Cisplatin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital].

[Transliterated title] El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital.

Anal cancers compromise only 1.5% of all digestive tumors.

OBJECTIVE: To collect and analyze clinical data from the medical records of all consecutive patients with squamous cell carcinoma of the anal canal (SCCAC) treated by the Oncology Section in 20 years.

[MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Anal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16127985.001).

[ISSN] 0300-9033

[Journal-full-title] Acta gastroenterologica Latinoamericana

[ISO-abbreviation] Acta Gastroenterol. Latinoam.

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Argentina

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Novel diagnostic methods for early-stage squamous cell carcinoma of the anal canal successfully resected by endoscopic submucosal dissection.

[MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colonoscopy / methods. Dissection / methods. Intestinal Mucosa / surgery

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Colonoscopy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19866431.001).

[ISSN] 1438-8812

[Journal-full-title] Endoscopy

[ISO-abbreviation] Endoscopy

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Related average imbalance patterns were found for clinically distinct entities, e.g. hepatocellular carcinomas (ca.) and ductal breast ca., as well as for histologically related entities (squamous cell ca. of different sites).

[MeSH-major] Carcinoma / genetics. Chromosome Aberrations. Chromosome Mapping

COS Scholar Universe. author profiles.

SciCrunch. BioSharing: Resource: Registry .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Hum Genet. 1988 Nov;80(3):235-46 [3192213.001]

[Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]

[Cites] Br J Cancer. 1999 Dec;81(8):1410-8 [10604741.001]

[Cites] Int J Oncol. 2000 Feb;16(2):383-99 [10639584.001]

[Cites] Am J Pathol. 2000 Mar;156(3):871-8 [10702404.001]

[Cites] J Pathol. 2000 Nov;192(3):301-6 [11054712.001]

[Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]

[Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]

[Cites] Bioinformatics. 2001 Dec;17(12):1228-9 [11751233.001]

[Cites] Anal Cell Pathol. 2001;23(1):29-37 [11790857.001]

[Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]

[Cites] Cancer Genet Cytogenet. 2002 May;135(1):63-90 [12072205.001]

[Cites] Anal Cell Pathol. 2002;24(2-3):77-87 [12446957.001]

[Cites] Int J Cancer. 2003 Jul 1;105(4):494-8 [12712440.001]

[Cites] Clin Cancer Res. 2003 May;9(5):1808-14 [12738738.001]

[Cites] Pathologica. 2003 Apr;95(2):71-82 [12768875.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1039-44 [14730057.001]

[Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]

[Cites] BMC Cancer. 2004 Feb 6;4:5 [15018632.001]

[Cites] Neoplasia. 2004 Mar-Apr;6(2):143-9 [15140403.001]

[Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]

[Cites] Cytogenet Genome Res. 2004;106(1):43-8 [15218240.001]

[Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):1-9 [15325087.001]

[Cites] J Korean Med Sci. 2004 Oct;19(5):682-7 [15483344.001]

[Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]

[Cites] Clin Genet. 1972;3(3):169-79 [4115505.001]

[Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]

[Cites] Hum Genet. 1993 Feb;90(6):584-9 [8383093.001]

[Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]

[Cites] Hum Mol Genet. 1993 Nov;2(11):1907-14 [8281155.001]

[Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]

[Cites] Cancer Res. 1994 Sep 1;54(17):4813-7 [8062283.001]

[Cites] Cancer Genet Cytogenet. 1995 Jul 15;82(2):140-5 [7664243.001]

[Cites] Blood. 1996 Jan 1;87(1):25-9 [8547649.001]

[Cites] Nat Genet. 1996 Apr;12(4):368-75 [8630489.001]

[Cites] Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:101-4 [8981013.001]

[Cites] Cytogenet Cell Genet. 1996;75(1):17-21 [8995481.001]

[Cites] Nat Genet. 1997 Apr;15(4):406-10 [9090389.001]

[Cites] J Neuropathol Exp Neurol. 1997 Sep;56(9):999-1008 [9291941.001]

[Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):372-6 [9408753.001]

[Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]

[Cites] Genes Chromosomes Cancer. 1998 Feb;21(2):172-5 [9491330.001]

[Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]

[Cites] Am J Hum Genet. 1998 Aug;63(2):625-37 [9683604.001]

[Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]

[Cites] Genes Chromosomes Cancer. 1998 Dec;23(4):307-16 [9824203.001]

[Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]

[Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1283-91 [16979954.001]

[Cites] Oncogene. 2006 Nov 23;25(55):7324-32 [16751803.001]

[Cites] J Pathol. 2007 Jan;211(1):18-25 [17072825.001]

[Cites] Lung Cancer. 2006 Dec;54(3):293-301 [17011066.001]

[Cites] Oncogene. 2007 Feb 8;26(6):934-44 [16862168.001]

[Cites] Bioinformatics. 2007 Feb 15;23(4):450-7 [17150994.001]

[Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):1-14 [17382262.001]

[Cites] Prostate. 2007 May 15;67(7):692-700 [17342750.001]

[Cites] Int J Cancer. 2007 Jun 15;120(12):2734-8 [17354231.001]

[Cites] Pathologe. 2007 Nov;28(6):464-73 [17882420.001]

[Cites] Ugeskr Laeger. 2008 Jan 28;170(5):328-30 [18252159.001]

[Cites] Hum Genet. 1988 Nov;80(3):224-34 [3192212.001]

[Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]

[Cites] Am J Hum Genet. 1960 Sep;12:250-76 [14430808.001]

[Cites] Thyroid. 2004 Dec;14(12):1061-4 [15650359.001]

[Cites] Cancer Res. 2005 Feb 1;65(3):822-7 [15705879.001]

[Cites] Acta Pharmacol Sin. 2005 Jun;26(6):659-65 [15916730.001]

[Cites] Int J Oncol. 2005 Sep;27(3):593-606 [16077907.001]

[Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):11-9 [16130125.001]

[Cites] Biotechniques. 2006 Mar;40(3):269-70, 272 [16568815.001]

[Cites] BMC Cancer. 2006;6:96 [16620391.001]

[Cites] Cancer Genet Cytogenet. 2006 Jun;167(2):103-8 [16737908.001]

[Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):721-30 [16688744.001]

[Cites] Clin Cancer Res. 2006 Jul 1;12(13):3961-70 [16818693.001]

[Cites] Cell Oncol. 2006;28(3):71-84 [16823176.001]

[Cites] Oncogene. 2006 Jul 27;25(32):4399-412 [16547504.001]

[Cites] Bioinformatics. 2006 Aug 15;22(16):1971-8 [16705014.001]

[Cites] Cytogenet Genome Res. 2006;115(1):16-22 [16974079.001]

[Cites] J Invest Dermatol. 2006 Oct;126(10):2308-15 [16728973.001]

(PMID = 18088415.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't

[Publication-country] England

[Other-IDs] NLM/ PMC2225423

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.

BACKGROUND: The integrin alphavbeta3 plays an important role in angiogenesis and tumor cell metastasis, and is currently being evaluated as a target for new therapeutic approaches.

Moreover, using the A431 human squamous cell carcinoma model we demonstrate that this approach is sensitive enough to visualize alphavbeta3 expression resulting exclusively from the tumor vasculature.

[MeSH-minor] Animals. Blotting, Western. Carcinoma, Squamous Cell / radionuclide imaging. Humans. Immunohistochemistry. Melanoma / radionuclide imaging. Mice. Neoplasms / blood supply. Neoplasms / pathology. Neovascularization, Pathologic. Positron-Emission Tomography. Sensitivity and Specificity. Skin Neoplasms / radionuclide imaging. Transplantation, Heterologous

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]

[Cites] Clin Cancer Res. 1998 Nov;4(11):2625-34 [9829725.001]

[Cites] J Nucl Med. 2005 Jan;46(1):184-9 [15632051.001]

[Cites] J Nucl Med. 1999 Nov;40(11):1771-7 [10565769.001]

[Cites] Adv Cancer Res. 2000;79:1-38 [10818676.001]

[Cites] Clin Cancer Res. 2000 Aug;6(8):3056-61 [10955784.001]

[Cites] Magn Reson Med. 2000 Sep;44(3):433-9 [10975896.001]

[Cites] J Nucl Med. 2001 Feb;42(2):326-36 [11216533.001]

[Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]

[Cites] Eur J Nucl Med. 2001 Feb;28(2):136-43 [11303882.001]

[Cites] Semin Oncol. 2001 Oct;28(5 Suppl 16):94-104 [11706401.001]

[Cites] Eur J Nucl Med Mol Imaging. 2002 Jan;29(1):28-38 [11807604.001]

[Cites] Int J Cancer. 2002 Apr 10;98(5):690-7 [11920637.001]

[Cites] Science. 2002 Jun 28;296(5577):2404-7 [12089446.001]

[Cites] Cell. 2002 Sep 6;110(5):599-11 [12230977.001]

[Cites] Bioconjug Chem. 2002 Sep-Oct;13(5):1021-30 [12236784.001]

[Cites] Calcif Tissue Int. 2002 Oct;71(4):293-9 [12154391.001]

[Cites] Expert Opin Biol Ther. 2002 Dec;2(8):953-66 [12517273.001]

[Cites] Nat Rev Cancer. 2002 Feb;2(2):83-90 [12635171.001]

[Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]

[Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):641-6 [12537667.001]

[Cites] Clin Exp Metastasis. 2003;20(3):203-13 [12741679.001]

[Cites] Chemistry. 2003 Jun 16;9(12):2717-25 [12772286.001]

[Cites] Q J Nucl Med. 2003 Sep;47(3):189-99 [12897710.001]

[Cites] Curr Opin Investig Drugs. 2003 Jun;4(6):741-5 [12901235.001]

[Cites] Angiogenesis. 2002;5(4):237-56 [12906317.001]

[Cites] Cancer Res. 2003 Sep 15;63(18):5838-43 [14522907.001]

[Cites] Oral Oncol. 2004 Feb;40(2):228-30 [14693249.001]

[Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]

[Cites] Nucl Med Biol. 2004 Jan;31(1):11-9 [14741566.001]

[Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]

[Cites] Curr Pharm Des. 2004;10(13):1439-55 [15134568.001]

[Cites] J Nucl Med. 2004 May;45(5):892-902 [15136641.001]

[Cites] J Nucl Med. 2004 Oct;45(10):1776-83 [15471848.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] J Biol Chem. 1987 Dec 25;262(36):17703-11 [2447074.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5819-23 [1712106.001]

[Cites] FEBS Lett. 1991 Oct 7;291(1):50-4 [1718779.001]

[Cites] Eur J Immunol. 2004 Jun;34(6):1608-16 [15162430.001]

[Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):231-44 [15186604.001]

[Cites] Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1081-9 [15118844.001]

[Cites] Mol Imaging. 2004 Apr;3(2):96-104 [15296674.001]

[Cites] Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9 [15380745.001]

[Cites] J Clin Invest. 1992 Jun;89(6):2018-22 [1376331.001]

[Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]

[Cites] Am J Pathol. 1994 Jun;144(6):1188-94 [7515558.001]

[Cites] Cell. 1994 Dec 30;79(7):1157-64 [7528107.001]

[Cites] J Clin Invest. 1995 Oct;96(4):1815-22 [7560073.001]

[Cites] Eur J Nucl Med. 1995 Dec;22(12):1420-32 [8586089.001]

[Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]

[Cites] Nat Med. 1998 May;4(5):623-6 [9585240.001]

[Cites] J Med Chem. 1999 Aug 12;42(16):3033-40 [10447947.001]

(PMID = 15783258.001).

[ISSN] 1549-1676

[Journal-full-title] PLoS medicine

[ISO-abbreviation] PLoS Med.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / fluorogalacto-RGD; X2RN3Q8DNE / Galactose

[Other-IDs] NLM/ PMC1069665

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer.

BACKGROUND AND PURPOSE: To investigate acute and late radiotherapy-related adverse events following intensity-modulated radiotherapy (IMRT) and high dose rate (HDR) brachytherapy of anal cancer.

MATERIALS AND METHODS: Fifty-nine consecutive patients treated by chemoradiotherapy for anal squamous cell cancer were evaluated for acute and late radiotherapy-related adverse events.

RESULTS: A significant reduction in skin and mucosal eruptions in the female genital area (P=0.04) and in radiotherapy-associated > grade 2 diarrhoea (P=0.004) was observed in patients treated by IMRT.

A correlation between the equivalent dose in 2Gy fractions (EQD2) at the wall of anal canal opposite to the tumour and radiation proctitis was observed.

CONCLUSIONS: IMRT significantly reduces acute radiotherapy-associated adverse events in patients treated by chemoradiotherapy for anal cancer.

[MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects

[MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiation Injuries. Radiotherapy Dosage

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18501454.001).

[ISSN] 0167-8140

[Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

[ISO-abbreviation] Radiother Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Ireland

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.

PURPOSE: The staging of anal cancer is extremely important for therapy and prognosis.

METHODS: Forty-five anal cancer patients underwent endoscopic ultrasound and magnetic resonance imaging.

Cancer patients were correctly identified with 100% sensitivity (45/45) by endoscopic ultrasound and with 88.9% (40/45) sensitivity by magnetic resonance imaging.

[MeSH-major] Anus Neoplasms / diagnostic imaging. Anus Neoplasms / pathology. Endosonography. Magnetic Resonance Imaging. Neoplasm Staging / methods

[MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Squamous Cell / diagnostic imaging. Carcinoma, Squamous Cell / pathology. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / diagnostic imaging. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - MRI Scans.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] World J Gastroenterol. 2008 Jun 14;14 (22):3504-10 [18567078.001]

[Cites] Surg Endosc. 2008 Nov;22(11):2412-5 [18622554.001]

[Cites] Int J Colorectal Dis. 2000 Nov;15(5-6):282-90 [11151431.001]

[Cites] Endoscopy. 1995 Sep;27(7):469-79 [8565885.001]

[Cites] Surg Endosc. 2000 Nov;14 (11):1005-9 [11116406.001]

[Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]

[Cites] World J Gastroenterol. 2007 Feb 14;13(6):895-900 [17352019.001]

[Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]

[Cites] Dis Colon Rectum. 1986 Apr;29(4):234-42 [3512199.001]

[Cites] Int J Colorectal Dis. 1991 Aug;6(3):152-7 [1744487.001]

[Cites] Clin Radiol. 2005 Oct;60(10):1111-9 [16179172.001]

[Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]

[Cites] Int J Colorectal Dis. 1992 Sep;7(3):122-4 [1402307.001]

[Cites] Int J Colorectal Dis. 2007 Oct;22(10 ):1261-8 [17294198.001]

[Cites] Int J Colorectal Dis. 1991 Feb;6(1):2-4 [2033348.001]

[Cites] Dis Colon Rectum. 1978 Mar;21(2):89-91 [648293.001]

[Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]

[Cites] AJR Am J Roentgenol. 2006 Jan;186(1):144-8 [16357394.001]

[Cites] Radiology. 2004 Sep;232(3):773-83 [15273331.001]

[Cites] Eur J Radiol. 2007 Mar;61(3):480-9 [17188828.001]

[Cites] N Engl J Med. 2003 Jun 19;348(25):2491-9 [12815134.001]

[Cites] Int J Colorectal Dis. 2007 Nov;22(11):1347-52 [17643251.001]

[Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]

[Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]

[Cites] Int J Colorectal Dis. 2007 Feb;22(2):191-9 [16799791.001]

[Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]

[Cites] Int J Colorectal Dis. 1992 Dec;7(4):192-6 [1293239.001]

[Cites] Dis Colon Rectum. 1974 Mar-Apr;17(2):181-7 [4819268.001]

[Cites] Radiol Med. 2003 Oct;106(4):329-37 [14612825.001]

[Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]

[Cites] Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5 [7215078.001]

[Cites] Radiology. 2007 Jan;242(1):137-43 [17090719.001]

[Cites] J Ultrasound Med. 2006 Jan;25(1):57-73 [16371556.001]

[Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]

[Cites] Radiology. 1990 May;175(2):494-8 [2326475.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]

[Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]

(PMID = 19365694.001).

[ISSN] 1873-4626

[Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

[ISO-abbreviation] J. Gastrointest. Surg.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men.

OBJECTIVES: To assess levels of episomal and integrated human papillomavirus type 16 (HPV-16) loads in HIV-seropositive men who have sex with men (MSM) in anal infection and to study the association between episomal and integrated HPV-16 loads and anal intraepithelial neoplasia (AIN).

Overall, 135 (54.7%) men provided 665 HPV-16-positive anal samples.

RESULTS: The HPV-16 DNA forms in anal samples were characterized as episomal only in 627 samples (94.3%), mixed in 22 samples (3.3%) and integrated only in nine samples (1.4%).

HPV-16 episomal load [odds ratio (OR) = 1.5, 95% confidence interval (CI) 1.1-2.1], number of HPV types (OR = 1.4, 95% CI 1.1-1.8) and current smoking (OR = 4.8, 95% CI 1.3-18.6) were associated with high-grade AIN (AIN-2,3) after adjusting for age and CD4 cell counts.

[MeSH-major] Anus Neoplasms / immunology. Carcinoma, Squamous Cell / immunology. HIV Seropositivity / immunology. Human papillomavirus 16 / immunology. Papillomavirus Infections / immunology. Plasmids / immunology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20706109.001).

[ISSN] 1473-5571

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] eng

[Grant] Canada / Canadian Institutes of Health Research / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Viral

[Investigator] Allaire G; Baril JG; Boissonnault M; Charest L; Charron MA; Coté S; Coté P; Coutlée F; de Pokomandy A; Dion H; Dufresne S; Falutz J; Fortin C; Franco EL; Ghattas G; Gilmore N; Gorska I; Hadjeres R; Junod P; Klein M; Lalonde R; Laplante F; Leblanc R; Legault D; Lessard B; Longpré D; McLeod J; Maziade JP; Murphy D; Nguyen VK; O'Brien R; Phaneuf D; Rouleau D; Routy JP; Szabo J; Tessier D; Thomas R; Toma E; Tremblay C; Trépanier JM; Trottier B; Tsoukas C; Turner H; Vezina S

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

We investigated mechanisms of acquired resistance to the EGFR TKI gefitinib by generating gefitinib-resistant (GR) A431 squamous cancer cells.

Inhibition of IGFIR signaling disrupted the association of IRS-1 with PI3K and restored the ability of gefitinib to downregulate PI3K/Akt signaling and to inhibit GR cell growth.

Addition of recombinant IGFBP-3 restored the ability of gefitinib to downregulate PI3K/Akt signaling and to inhibit cell growth.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]

[Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]

[Cites] J Clin Oncol. 2005 Apr 10;23(11):2493-501 [15710947.001]

[Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]

[Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]

[Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70 [15897464.001]

[Cites] Clin Cancer Res. 2005 Jun 1;11(11):4182-90 [15930355.001]

[Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]

[Cites] Mol Cell Biol. 2004 Aug;24(16):7275-83 [15282325.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]

[Cites] J Clin Invest. 1985 Oct;76(4):1643-8 [4056043.001]

[Cites] Anal Biochem. 1986 Apr;154(1):138-43 [2422981.001]

[Cites] J Natl Cancer Inst. 1992 Sep 2;84(17):1336-41 [1379645.001]

[Cites] Nat Med. 1999 Jul;5(7):810-6 [10395327.001]

[Cites] Cancer Res. 2004 Nov 1;64(21):7711-23 [15520175.001]

[Cites] Int J Cancer. 2005 Jan 10;113(2):316-28 [15386423.001]

[Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]

[Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]

[Cites] Eur J Cancer. 2005 Jul;41(11):1515-27 [15979304.001]

[Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]

[Cites] Cancer Cell. 2005 Oct;8(4):287-97 [16226704.001]

[Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]

[Cites] Cell. 2006 May 19;125(4):733-47 [16647110.001]

[Cites] Nat Rev Genet. 2006 Aug;7(8):606-19 [16847462.001]

[Cites] J Clin Invest. 2006 Oct;116(10):2695-706 [16906227.001]

[Cites] Clin Cancer Res. 2006 Oct 1;12(19):5764-9 [17020982.001]

[Cites] Clin Cancer Res. 2006 Nov 1;12(21):6494-501 [17085664.001]

[Cites] J Biol Chem. 2006 Dec 29;281(52):40183-92 [17082181.001]

[Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]

[Cites] Cancer Res. 2007 Jun 15;67(12):5779-88 [17575145.001]

[Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4637-40 [17671156.001]

[Cites] Cancer Res. 2007 Aug 15;67(16):7807-14 [17699786.001]

[Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]

[Cites] Cancer Biol Ther. 2007 Apr;6(4):534-40 [17457048.001]

[Cites] Int J Cancer. 2008 Feb 1;122(3):558-66 [17918155.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7 [18093943.001]

[Cites] Oncogene. 2008 Apr 3;27(15):2137-47 [17952116.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 [15731348.001]

[Cites] J Cell Physiol. 2000 Apr;183(1):1-9 [10699960.001]

[Cites] Blood. 2002 Oct 15;100(8):3041-4 [12351420.001]

[Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]

[Cites] Oncogene. 2003 May 8;22(18):2812-22 [12743604.001]

[Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]

[Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]

[Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]

[Cites] Cancer Cell. 2004 Mar;5(3):231-9 [15050915.001]

[Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]

[CommentIn] J Clin Invest. 2008 Jul;118(7):2389-92 [18568082.001]

(PMID = 18568074.001).

[ISSN] 0021-9738

[Journal-full-title] The Journal of clinical investigation

[ISO-abbreviation] J. Clin. Invest.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA080195; United States / NCI NIH HHS / CA / P50 CA98131; United States / NCI NIH HHS / CA / P30 CA68485; United States / NCI NIH HHS / CA / R01 CA80195; United States / NCI NIH HHS / CA / P50 CA098131; United States / NCI NIH HHS / CA / K08 CA120060; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / R00 CA125892; United States / NCI NIH HHS / CA / K08 CA120060-01; United States / NCI NIH HHS / CA / P50 CA127003

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Insulin-Like Growth Factor Binding Protein 4; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Irs1 protein, mouse; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; S65743JHBS / gefitinib

[Other-IDs] NLM/ PMC2430495

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term quality of life after radiotherapy for the treatment of anal cancer.

BACKGROUND: Radiotherapy is the current standard of care for patients with localized squamous cell cancer of the anal canal.

METHODS: Questionnaires were mailed to 80 patients treated with definitive radiotherapy, with or without concurrent chemotherapy, for anal cancer, with a minimum 2-year interval after the completion of radiotherapy.

The questionnaire included the Functional Assessment of Cancer Therapy-Colorectal (FACT-C), the Medical Outcomes Study (MOS) Sexual Problems Scale, and questions regarding demographic characteristics and comorbidities.

The median total FACT-C score was 108 (range, 47-128), of a maximum (best possible) score of 136.

The median score on the MOS Sexual Problems Scale was 67 (range, 0-100), of a maximum (worst possible) score of 100.

CONCLUSIONS: Patients treated with radiotherapy for anal cancer reported acceptable overall QoL scores, but poor sexual function scores.

[MeSH-major] Anus Neoplasms / psychology. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / radiotherapy. Quality of Life

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20041481.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA16672

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.

BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.

We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.

METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.

Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.

CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.

[MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]

[Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]

[Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]

[Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]

[Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]

[Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]

[Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]

[Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]

[Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]

[Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]

[Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]

[Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]

[Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]

[Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]

[Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]

[Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]

[Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]

(PMID = 20137093.001).

[ISSN] 1748-717X

[Journal-full-title] Radiation oncology (London, England)

[ISO-abbreviation] Radiat Oncol

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18

[Other-IDs] NLM/ PMC2851594

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell Cycle. 2007 Feb 1;6(3):305-11 [17224650.001]

[Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]

[Cites] Cell Cycle. 2007 Feb 1;6(3):274-85 [17264681.001]

[Cites] Cell Cycle. 2007 Feb 1;6(3):240-5 [17297296.001]

[Cites] Cell Cycle. 2007 Feb 1;6(3):246-54 [17297308.001]

[Cites] Cell Cycle. 2007 Apr 15;6(8):931-42 [17457059.001]

[Cites] J Clin Invest. 2007 May;117(5):1370-80 [17446929.001]

[Cites] Cell Cycle. 2007 May 2;6(9):1062-71 [17426453.001]

[Cites] Cell Cycle. 2006 Nov 1;5(21):2489-94 [17106255.001]

[Cites] Cancer Res. 2007 Jul 1;67(13):6325-32 [17616691.001]

[Cites] Cell Cycle. 2007 Aug 1;6(15):1831-6 [17671427.001]

[Cites] Mol Cell Biol. 2000 May;20(9):3224-33 [10757806.001]

[Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7 [10805802.001]

[Cites] Oncogene. 2000 Jun 22;19(27):3126-30 [10871867.001]

[Cites] J Biol Chem. 2000 Jul 28;275(30):22719-27 [10801797.001]

[Cites] Cancer Res. 2000 Aug 1;60(15):4016-20 [10945600.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1817-22 [11172034.001]

[Cites] Nat Biotechnol. 2001 Apr;19(4):375-8 [11283598.001]

[Cites] Oncogene. 2001 Apr 5;20(15):1803-15 [11313928.001]

[Cites] Eur J Biochem. 2001 May;268(10):2764-72 [11358490.001]

[Cites] Mol Pharmacol. 2001 Sep;60(3):405-15 [11502869.001]

[Cites] Apoptosis. 2007 Oct;12(10):1847-55 [17636382.001]

[Cites] Cell Cycle. 2007 Oct 1;6(19):2339-40 [17914283.001]

[Cites] Cell Cycle. 2007 Dec 15;6(24):3114-31 [18075315.001]

[Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]

[Cites] Cell Cycle. 2008 May 1;7(9):1231-7 [18418053.001]

[Cites] Cell Cycle. 2008 May 15;7(10):1353-9 [18418074.001]

[Cites] Cell Cycle. 2004 Jan;3(1):80-9 [14657672.001]

[Cites] J Biol Chem. 2003 Dec 19;278(51):51408-14 [14555649.001]

[Cites] Oncogene. 2004 Mar 11;23(10):1829-37 [14647429.001]

[Cites] Annu Rev Biochem. 2004;73:39-85 [15189136.001]

[Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]

[Cites] Methods Enzymol. 1991;200:3-37 [1835513.001]

[Cites] J Biol Chem. 1995 Sep 8;270(36):21396-403 [7545671.001]

[Cites] Eur J Biochem. 1997 Jan 15;243(1-2):518-26 [9030780.001]

[Cites] Eur J Biochem. 1997 Jan 15;243(1-2):527-36 [9030781.001]

[Cites] Science. 1998 Sep 11;281(5383):1674-7 [9733514.001]

[Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]

[Cites] Cancer Res. 1999 Jun 15;59(12):2781-6 [10383130.001]

[Cites] J Virol. 2004 Dec;78(24):13501-11 [15564461.001]

[Cites] Cancer Res. 2004 Dec 15;64(24):9152-9 [15604286.001]

[Cites] Cell Cycle. 2004 Oct;3(10):1285-95 [15467455.001]

[Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]

[Cites] J Biol Chem. 1999 Dec 31;274(53):37538-43 [10608806.001]

[Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]

[Cites] J Biol Chem. 2000 Mar 17;275(11):7803-10 [10713094.001]

[Cites] J Biol Chem. 2001 Aug 24;276(34):31819-24 [11431470.001]

[Cites] Curr Opin Chem Biol. 2001 Oct;5(5):591-602 [11578935.001]

[Cites] J Biol Chem. 2001 Nov 9;276(45):41717-24 [11546792.001]

[Cites] Nat Biotechnol. 2002 Mar;20(3):301-5 [11875433.001]

[Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]

[Cites] Exp Cell Res. 2002 Jun 10;276(2):194-200 [12027449.001]

[Cites] Cancer Cell. 2002 May;1(4):369-79 [12086851.001]

[Cites] Neoplasia. 2002 Sep-Oct;4(5):400-8 [12192598.001]

[Cites] Cell Cycle. 2002 May-Jun;1(3):162-8 [12429926.001]

[Cites] Anal Chem. 2002 Nov 1;74(21):5593-9 [12433093.001]

[Cites] Mol Cell Biol. 2003 Apr;23(7):2264-76 [12640112.001]

[Cites] J Biol Chem. 2003 Apr 4;278(14):12207-13 [12519769.001]

[Cites] Cancer Res. 2003 May 15;63(10):2351-7 [12750249.001]

[Cites] Laryngoscope. 2003 Jun;113(6):936-9 [12782800.001]

[Cites] Oncogene. 2003 Jun 5;22(23):3635-44 [12789272.001]

[Cites] Prog Cell Cycle Res. 2003;5:235-48 [14593718.001]

[Cites] Cell Cycle. 2004 Nov;3(11):1358-62 [15492512.001]

[Cites] Cancer Res. 2005 Feb 1;65(3):758-66 [15705872.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5056-61 [15788536.001]

[Cites] Nat Cell Biol. 2005 May;7(5):493-500 [15834407.001]

[Cites] Cell Cycle. 2005 May;4(5):710-6 [15846104.001]

[Cites] J Biol Chem. 2005 Jul 8;280(27):25485-90 [15899889.001]

[Cites] EMBO J. 2005 Jul 6;24(13):2458-71 [15944736.001]

[Cites] Mol Cancer. 2005;4(1):25 [16033649.001]

[Cites] Oncogene. 2005 Oct 20;24(46):6970-5 [16007154.001]

[Cites] Int J Mol Med. 2005 Dec;16(6):1065-70 [16273287.001]

[Cites] Cell Cycle. 2005 Oct;4(10):1313-5 [16123597.001]

[Cites] Cell Cycle. 2005 Oct;4(10):1440-7 [16177572.001]

[Cites] Neuron. 2005 Dec 8;48(5):743-56 [16337913.001]

[Cites] Nat Cell Biol. 2006 Jan;8(1):37-45 [16327781.001]

[Cites] Cancer Cell. 2006 Jan;9(1):1-2 [16413463.001]

[Cites] Cancer Cell. 2006 Jan;9(1):45-56 [16413471.001]

[Cites] Methods Enzymol. 2005;405:82-115 [16413312.001]

[Cites] Curr Opin Genet Dev. 2006 Feb;16(1):38-44 [16359856.001]

[Cites] Cell Cycle. 2006 Jun;5(12):1342-7 [16760655.001]

[Cites] Laryngoscope. 2006 Aug;116(8):1390-6 [16885742.001]

[Cites] Laryngoscope. 2006 Aug;116(8):1409-16 [16885745.001]

[Cites] Cancer Res. 2006 Aug 15;66(16):7870-9 [16912160.001]

[Cites] Development. 2006 Dec;133(23):4783-92 [17079275.001]

(PMID = 18769144.001).

[ISSN] 1551-4005

[Journal-full-title] Cell cycle (Georgetown, Tex.)

[ISO-abbreviation] Cell Cycle

[Language] ENG

[Grant] United States / NIDCR NIH HHS / DE / DE013561-08; United States / NIDCR NIH HHS / DE / R01 DE013561; United States / NIDCR NIH HHS / DE / R01 DE013561-08

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 1114-81-4 / Phosphothreonine; 17885-08-4 / Phosphoserine; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; Q20Q21Q62J / Cisplatin

[Other-IDs] NLM/ NIHMS280819; NLM/ PMC3069617